BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parikh ND, Levitsky J. Hepatotoxicity and drug interactions in liver transplant candidates and recipients. Clin Liver Dis 2013;17:737-47, x-xi. [PMID: 24099028 DOI: 10.1016/j.cld.2013.07.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, Miller C. A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients. Infect Dis Ther. 2015; Jan 28. [Epub ahead of print]. [PMID: 25708155 DOI: 10.1007/s40121-015-0058-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
2 Fenkel JM, Halegoua-DeMarzio DL. Management of the Liver Transplant Recipient: Approach to Allograft Dysfunction. Med Clin North Am 2016;100:477-86. [PMID: 27095640 DOI: 10.1016/j.mcna.2016.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clinics in Liver Disease 2017;21:1-20. [DOI: 10.1016/j.cld.2016.08.001] [Cited by in Crossref: 151] [Cited by in F6Publishing: 135] [Article Influence: 30.2] [Reference Citation Analysis]
4 Ganesh S, Almazroo OA, Tevar A, Humar A, Venkataramanan R. Drug Metabolism, Drug Interactions, and Drug-Induced Liver Injury in Living Donor Liver Transplant Patients. Clin Liver Dis 2017;21:181-96. [PMID: 27842771 DOI: 10.1016/j.cld.2016.08.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Pedersen M, Seetharam A. Infections after orthotopic liver transplantation. J Clin Exp Hepatol. 2014;4:347-360. [PMID: 25755581 DOI: 10.1016/j.jceh.2014.07.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
6 Luo J, Xie M, Hou Y, Ma W, Jin Y, Chen J, Li C, Zhao K, Chen N, Xu L, Ji Y, Zhang Q, Zheng Y, Yu D. A novel epigenetic mechanism unravels hsa-miR-148a-3p-mediated CYP2B6 downregulation in alcoholic hepatitis disease. Biochem Pharmacol 2021;188:114582. [PMID: 33895159 DOI: 10.1016/j.bcp.2021.114582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 van Nuland M, Janssen JM, van Hoek B, Rosing H, Beijnen JH, Bergman AM. Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. Clin Genitourin Cancer 2019;17:e893-6. [PMID: 31248829 DOI: 10.1016/j.clgc.2019.05.026] [Reference Citation Analysis]